BackgroundBiologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.MethodsIn a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis to determine whether vedolizumab was superior. Previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25% of patients. The patients were assigned to receive infusions of 300 mg of vedolizumab on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46 (plus injections of placebo) or subcutaneous injections of 40 mg of adalim...
Background & AimsThe efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal an...
Background & Aims: Clinicians face difficulty in when and in what order to position biologics an...
Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under...
BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head tria...
BackgroundBiologic therapies are widely used in patients with ulcerative colitis. Head-to-head trial...
Background: Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head tri...
Aim: Indirect comparison of efficacy and safety of vedolizumab with adalimumab in biologic-naïve pat...
There are no prospective, head-to-head, controlled trials comparing the efficacy and safety of Infli...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background & aimsWe aimed to compare safety and effectiveness of vedolizumab to tumor necrosis f...
BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcera...
Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance tr...
Background and aims There are limited comparative data for infliximab and vedolizuma...
BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's dise...
Background & AimsThe efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal an...
Background & Aims: Clinicians face difficulty in when and in what order to position biologics an...
Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under...
BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head tria...
BackgroundBiologic therapies are widely used in patients with ulcerative colitis. Head-to-head trial...
Background: Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head tri...
Aim: Indirect comparison of efficacy and safety of vedolizumab with adalimumab in biologic-naïve pat...
There are no prospective, head-to-head, controlled trials comparing the efficacy and safety of Infli...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background & aimsWe aimed to compare safety and effectiveness of vedolizumab to tumor necrosis f...
BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcera...
Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance tr...
Background and aims There are limited comparative data for infliximab and vedolizuma...
BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's dise...
Background & AimsThe efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal an...
Background & Aims: Clinicians face difficulty in when and in what order to position biologics an...
Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under...